In vitro model of metastasis to bone marrow mediates prostate cancer castration resistant growth through paracrine and extracellular matrix factors

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Lescarbeau, Reynald M ^a   Seib, F Philipp ^a   Prewitz, Marina ^b   Werner, Carsten ^b   Kaplan, David L ^a  

^a Tufts University   (United States)

^b LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SCLEROPROTEIN; VITRONECTIN RECEPTOR;

ARTICLE; BONE MARROW; BONE MARROW METASTASIS; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; OSTEOBLAST; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANDROGENS; APOPTOSIS; BONE MARROW NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; EXTRACELLULAR MATRIX; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STROMAL CELLS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PARACRINE COMMUNICATION; PHOSPHORYLATION; PROSTATIC NEOPLASMS;

EID: 84864751521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040372     Document Type: Article

References (27)

1. Logothetis CJ, Lin SH, (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Can 5: 21-28.
2. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, et al. (2004) Osteoblast derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 10: 1860-1869.
3. Vincent T, Mechti N, (2005) Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leukemia Lymphoma 46: 803-811.
4. Andersen C, Bagi CM, Adams SW, (2003) Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats. J Musculoskel Neuron Interact 3: 148-155.
5. Moreau JE, Anderson K, Mauney JR, Nguygen T, Kaplan DL, et al. (2007) Tissue-Engineered Bone Serves as a Target for Metastasis of Human Breast Cancer in a Mouse Model. Cancer Res 67: 10304-10308.
6. Wang G, Haile S, Comuzzi B, Tien AH, Wang J, et al. (2009) Osteoblast-derived factors Induce an expression signature that identifies prostate cancer metastasis and hormonal progression. Cancer Res 69: 3433-3442.
7. Lee SO, Lou W, Johnson CS, Trump D, Gao A, (2004) Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 60: 178-186.
8. Reichert JC, Quent VMC, Burke LJ, Stansfield SH, Clements JA, et al. (2010) Mineralized human primary osteoblast matrices as a model system to analyze interactions of prostate cancer cells with the bone microenvironment. Biomaterials 31: 7928-7936.
9. Pathi SP, Kowalczewski C, Tadipatri R, Fischbach C, (2010) A novel 3-D mineralized tumor model to study breast cancer metastasis. Plos ONE 5: 8849.
10. Mostaghel EA, Nelson PS, (2008) Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Clin Endo Meta 22: 243-258.
11. Wang G, Wang J, Sadar MD, (2008) Crosstalk between the androgen receptor and β-catenin in castrate-resistant prostate cancer. Cancer Res 68: 9918-9927.
12. Zhu M, Kyprianou N, (2008) Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endo related cancer 15: 841-849.
13. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, et al. (2003) PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 162: 281-291.
14. Thomas F, Holly JM, Persad R, Bahl A, Perks CM, (2010) Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate 70: 856-865.
15. Altman GH, Horan RL, Lu HH, Moreau J, Matin I, et al. (2002) Silk matrix for tissue engineered anterior cruciate ligaments. Biomaterials 23: 4131-4141.
16. Chen X, Dusevich V, Feng J, Manolagas SC, Jilka RL, (2007) Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation in osteoblasts. JBMR 22: 1943-1956.
17. Seib FP, Muller K, Franke M, Grimmer M, Bornhauser M, et al. (2009) Engineered Extracellular Matrices Modulate the Expression Profile and Feeder Properties of Bone Marrow-Derived Human Multipotent Mesenchymal Stromal Cells. Tiss Eng A 15: 3161-3171.
18. Seib FP, Franke M, Jing D, Werner C, Bornhauser M, (2009) Endogenous bone morphogenetic proteins in human bone marrow-derived multipotent mesenchymal stromal cells. European J Cell Bio 88: 257-71.
19. Charafe-Jauffret E, Tarpin C, Bardou V, Bertucci F, Ginestier C, et al. (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathology 202: 265-73.
20. Yang J, FIzazi K, Peleg S, Sikes CR, Raymond K, et al. (2001) Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Can Res 61: 5652-5659.
21. Cooper CR, Chay CH, Pienta KJ, (2002) The role of αvβ3 in prostate cancer progression. Neoplasia 4: 191-194.
22. Murillo H, Huang H, Schmidt LJ, Smith D, Tindall DJ, (2001) Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142: 4795-4805.
23. Harma V, Virtanen J, Makela R, Happonen A, Mpindi J, et al. (2010) A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion, and drug responses. PLOS one 5: 10431.
24. Lee JT, Steelman LS, McCubrey JA, (2005) Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. Int J Oncol 26: 1637-1644.
25. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zalivianki S, et al. (2006) Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endo related Can 13: 151-167.
26. Martin-Orozco RM, Almaraz-Pro C, Rodriguez-Ubreva F, Cortes MA, Ropero S, et al. (2007) EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia 9: 614-614.
27. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, et al. (2009) Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: Roles of ERK/MAP kinase. Prostate 69: 949-955.